CoreCap Advisors LLC Has $2.77 Million Stock Holdings in Abbott Laboratories $ABT

CoreCap Advisors LLC lowered its holdings in Abbott Laboratories (NYSE:ABT) by 27.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 22,107 shares of the healthcare product maker’s stock after selling 8,544 shares during the quarter. CoreCap Advisors LLC’s holdings in Abbott Laboratories were worth $2,770,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Cloud Capital Management LLC acquired a new stake in shares of Abbott Laboratories in the third quarter worth $29,000. Guerra Advisors Inc acquired a new position in Abbott Laboratories during the 3rd quarter valued at $31,000. Delos Wealth Advisors LLC bought a new stake in Abbott Laboratories in the 2nd quarter valued at $32,000. Bridge Generations Wealth Management LLC acquired a new stake in Abbott Laboratories in the 3rd quarter worth $33,000. Finally, Copia Wealth Management bought a new position in shares of Abbott Laboratories during the 3rd quarter worth about $38,000. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Trading Down 0.4%

ABT stock opened at $104.12 on Friday. Abbott Laboratories has a 1-year low of $102.41 and a 1-year high of $139.06. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The business’s 50 day moving average is $110.82 and its 200-day moving average is $122.13. The firm has a market cap of $181.35 billion, a P/E ratio of 27.99, a P/E/G ratio of 1.66 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same period in the prior year, the business posted $1.34 earnings per share. The business’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, EVP Mary K. Moreland sold 613 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the sale, the executive vice president directly owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. This represents a 0.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel J. Starks acquired 10,000 shares of the company’s stock in a transaction dated Wednesday, February 4th. The shares were purchased at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the acquisition, the director owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. This represents a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

ABT has been the subject of several research reports. Raymond James Financial reduced their target price on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Piper Sandler lowered their price target on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research note on Friday, January 23rd. Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 29th. Royal Bank Of Canada decreased their price objective on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Finally, Sanford C. Bernstein cut their target price on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $136.16.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.